{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021979","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.029394+00:00","generated_at":"2026-06-15T01:18:17.855130+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spruce Biosciences Q1 net loss $12.8M; CAH trials near enrollment goals; PCOS study topline Q3 2023","bullets":["Cash and investments $118.6M as of March 31, 2023; with Kaken $15M upfront, runway into H1 2025.","Collaboration revenue $2.0M (Kaken deal); R&D $11.7M; net loss $12.8M vs $11.8M YoY.","CAHmelia-204 (adult CAH) 50% enrolled; CAHmelia-203 approaching 75% enrollment.","P.O.W.E.R. PCOS Phase 2 fully enrolled (27 subjects); topline results expected Q3 2023.","Appointed Mo Noursalehi, Ph.D., as SVP of Biometrics; completed $53.6M private placement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021979","json":"https://secwatch.observer/filing/0000950170-23-021979.json","markdown":"https://secwatch.observer/filing/0000950170-23-021979.md","text":"https://secwatch.observer/filing/0000950170-23-021979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023021979/0000950170-23-021979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023021979/sprb-20230515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:18:17.855130+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5459ef69cc942b8d98740bdcc5e24f6371bf70c2","claim":"SPRUCE BIOSCIENCES, INC. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 15, 2023, Spruce Biosciences, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended March 31, 2023 and providing corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023021979/0000950170-23-021979-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}